Blood
Articles in this Issue
Approaching a therapeutic inflection point for <i>FLT3</i>-mutated AML
Abstract Combining FMS-like tyrosine kinase 3 (FLT3) inhibitors with intensive chemotherapy and transplant has substantially improved acute myeloid leukemia (AML) outcomes, prompting...
Introduction to a <i>Blood</i> Spotlight series on acute myeloid leukemia
Recent molecular and diagnostic advances in acute myeloid leukemia (AML) have led investigators and clinicians to further categorize patients in different subgroups, guiding therapeutic interventions....
NOTCH1 dimeric signaling is essential for T-cell leukemogenesis and leukemia maintenance
Abstract T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy that is characterized by an expansion of T-cell progenitors and DNA mutations that lead to overactive...
Chronic GVHD: one more promising player enters the arena
Sickle cell disease and diabetes mellitus
Connecting the DOT1L: it’s EZH2
Diabetes mellitus and <i>APOL1</i> genotype increase the risk for chronic kidney disease progression in sickle cell disease
Abstract We observed diabetes mellitus (DM) in 9.3% of adults with sickle cell disease (SCD), and DM predicted a sevenfold greater risk of chronic kidney disease progression adjustin...
The fit older adult with acute myeloid leukemia: clinical challenges to providing evidence-based frontline treatment
Abstract Recent advances in acute myeloid leukemia (AML) come from studies investigating older adults aged &lt;60 years, those aged ≥75 years, or less fit adults. Uncertainty exi...
A small B-cell leukemia/lymphoma with weak to negative expression of CD5
Deficiency of T follicular helper cell <i>Tet3</i> DNA demethylation inhibits pathogenic IgG2c class switching and chronic GVHD
Abstract Chronic graft-versus-host disease (cGVHD) is the leading cause of morbidity and nonrelapse-associated mortality after allogeneic hematopoietic cell transplantation. Treating...
TET3 stirs up trouble via pathogenic Ig class switching
Surface pTα expression predicts LCK activation and preclinical synergy of LCK and JAK coinhibition in adult T-ALL
Abstract Refractory and/or relapsing T-cell acute lymphoblastic leukemia (T-ALL) remains a major therapeutic challenge. The pre–T-cell receptor (TCR) pathway has recently emerged as...
Synergistic antitumor effect of combined EZH2 and DOT1L inhibition in B-cell lymphoma
Abstract Despite the approval of several new treatments for patients with B-cell lymphoma, there is still a large unmet need. Diffuse large B-cell lymphoma (DLBCL) and follicular lym...
<i>TP53</i>-mutated acute myeloid leukemia: how can we improve outcomes?
Abstract Despite advances in the treatment paradigm of patients with acute myeloid leukemia (AML), TP53-mutated AML represents a molecular subgroup that has failed to improve, with a...
Predicting T-ALL response to pre-TCR and IL-7R coinhibition
A first-in-class JAK/ROCK inhibitor, rovadicitinib, for glucocorticoid-refractory or -dependent chronic GVHD
Abstract Rovadicitinib (TQ05105) is a novel, oral dual Janus kinase 1/2 and rho-associated coiled-coil–containing protein kinase-1/2 inhibitor targeting inflammatory and fibrotic com...
Safety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: the phase 3 LUNA3 study
Abstract Rilzabrutinib is a covalent, reversible Bruton tyrosine kinase inhibitor targeting multiple immune thrombocytopenia (ITP)-related mechanisms. The phase 3 LUNA3 study in prev...
Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in adults over 70 years old
Abstract The advent of reduced-intensity conditioning regimens, improvements in graft-versus-host disease prophylaxis, and better supportive care have permitted increasing use of all...